About RLS
RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an
unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both
genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms
are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause
of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in
the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the
symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.
Technavio's analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers
the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.
Technavio's report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the
Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors
operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Boehringer Ingelheim
• GlaxoSmithKline
• UCB
• XenoPort
Other prominent vendors
• Alexza Pharmaceuticals
• Astellas Pharma
• Axxonis Pharma
• Bayer Healthcare
• Impax Pharmaceuticals
• Luitpold Pharmaceuticals
• Merz Pharmaceuticals
• Mundipharma
• Newron Pharmaceuticals
• Serina Therapeutics
• Teva Neuroscience
Market driver
• High unmet medical needs
• For a full, detailed list, view our report
Market challenge
• Unknown disease etiology
• For a full, detailed list, view our report
Market trend
• Expected entry of drugs with multiple mechanisms and novel technologies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1 MirapexSifrolMirapexin
05.2 Requip
05.3 NeuproLeganto
05.4 HORIZANTRegnite
06. Introduction
07. Disease Overview
07.1 Understanding RLS
07.1.1 Types of RLS
07.2 Etiology and Pathogenesis
07.2.1 Genetic Factors
07.2.2 Iron Deficiency
07.2.3 Other Disease ConditionsMedications
07.2.4 Neurological Disturbances
07.3 Signs and Symptoms
07.4 Diagnosis
07.4.1 Differential Diagnosis of RLS
07.5 Management
07.5.1 Pharmacological Therapy
07.5.2 Non-pharmacological Therapy
07.6 Epidemiology
07.7 Economic Burden
08. Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 Injectafer
08.1.2 Lisuride
08.1.3 Incobotulinumtoxin A
08.1.4 IPX-159
08.1.5 Safinamide
08.1.6 AZ-008
08.1.7 SER-214
09. Commercial Opportunities
10. Key Brand Analysis
11. Market Landscape
11.1 Market Overview
11.2 Market Size and Forecast
11.3 Five Forces Analysis
12. Market Segmentation by Class of Drugs
12.1 Dopaminergic Drugs
12.2 Opioids
12.3 Anticonvulsants
12.4 Sedatives and Hypnotics
12.5 Others
13. Geographical Segmentation
13.1 Global Restless Legs Syndrome Market by Geography 2014-2019
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 UCB
21.2.2 GlaxoSmithKline
21.2.3 Boehringer Ingelheim
21.2.4 XenoPort
21.3 Other and Future Prominent Vendors
22. Key Vendor Analysis
22.1 Boehringer Ingelheim
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Business Segmentation by Revenue 2013
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Geographical Segmentation by Revenue 2013
22.1.6 Business Strategy
22.1.7 Recent Developments
22.1.8 SWOT Analysis
22.2 GlaxoSmithKline
22.2.1 Key facts
22.2.2 Business overview
22.2.3 Business segmentation by revenue 2014
22.2.4 Business segmentation by revenue 2013 and 2014
22.2.5 Geographical segmentation by revenue 2014
22.2.6 Business strategy
22.2.7 Recent developments
22.2.8 SWOT analysis
22.3 UCB
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Product Segmentation by Revenue 2013
22.3.4 Product Segmentation by Revenue 2012 and 2013
22.3.5 Geographical Segmentation by Revenue 2013
22.3.6 Business Strategy
22.3.7 Recent Developments
22.3.8 SWOT Analysis
22.4 XenoPort
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Strategy
22.4.4 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Types of RLS
Exhibit 3: Prevalence of Primary and Secondary RLS 2014
Exhibit 4: Types of RLS based on Onset of Disease
Exhibit 5: Etiology of RLS
Exhibit 6: Symptoms of RLS
Exhibit 7: Differential Diagnosis of RLS
Exhibit 8: Treatment Options for RLS
Exhibit 9: Prevalence of RLS Based on Gender
Exhibit 10: Pipeline Portfolio of Global Restless Legs Syndrome Market
Exhibit 11: Commercial Opportunities for Global Restless Legs Syndrome Market
Exhibit 12: Global Restless Legs Syndrome Market 2014-2019 ($ millions)
Exhibit 13: Global Restless Legs Syndrome Market by Class of Drugs
Exhibit 14: Global Restless Legs Syndrome Market by Geography 2014
Exhibit 15: Vendor Ranking 2014
Exhibit 16: Neupro: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 17: Neupro: Region-wise Revenue Comparison 2012-2014 ($ millions)
Exhibit 18: Requip: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 19: Region-wise Revenue Comparison of Requip 2012-2014 ($ millions)
Exhibit 20: HORIZANT: US Revenue 2013-2014 ($ millions)
Exhibit 21: Regnite: Revenue in Japan 2013-2014 ($ millions)
Exhibit 22: Boehringer Ingelheim: Business Segmentation by Revenue 2013
Exhibit 23: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 24: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
Exhibit 25: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 27: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 28: UCB: Product Segmentation by Revenue 2013
Exhibit 29: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 30: UCB: Geographical Segmentation by Revenue 2013
